Introduction
Obesity is associated with increased mortality from a variety of cancers. 1 In pediatric acute lymphoblastic leukemia (ALL), obesity at the time of diagnosis has similarly been associated with an increased risk of relapse and poorer event free survival (EFS). [2] [3] [4] [5] As opposed to traditional host or biologic predictors of survival, however, weight and body composition fluctuate over the multiple years of ALL-directed therapy. 6, 7 We have recently shown that duration of obesity during the initial intensive months of chemotherapy independently predicts EFS. 3 Whether obesity poses a uniform risk during this period or whether it contributes greater influence during certain phases of treatment has yet to be investigated. On modern treatment regimens for ALL, disease response to initial chemotherapy as measured by end-induction minimal residual disease (MRD) in the bone marrow is among the strongest predictors of EFS. 8, 9 Due to the association between obesity and EFS, and the prognostic significance of endinduction MRD, we hypothesized that obesity during induction is associated with persistent leukemia as evidenced by end-induction MRD positivity in the bone marrow.
Recent studies from our group have described the "active" nature of adipocytes in the regulation of chemotherapy response in ALL cell lines and provide the rationale for such an effect. [10] [11] [12] To our knowledge, this is the first study examining the association of obesity and end-induction MRD.
Methods

Study Cohort
Children between the ages of 1 and 21 years diagnosed with ALL between January 2008 and January 2013 at Children's Hospital Los Angeles were included in this analysis of a historical cohort. Infant leukemia, acute leukemia of ambiguous lineage (ALAL), and Philadelphia Chromosome (BCR-ABL) positive B-precursor leukemia (PH+ALL) were excluded from analysis due to their unique leukemia biology and associated risk characteristics. T-cell ALL was similarly considered a distinct disease 13 and excluded due to a limited sample size. Patients with B-precursor ALL (BP-ALL)
were classified per National Cancer Institute/Rome criteria (NCI/Rome) 14 The study was reviewed and approved by the hospital Institutional Review Board, and was conducted in accordance with the Declaration of Helsinki.
Weight Classification
Height and weight at diagnosis and at the end of induction were used to calculate each child's body mass index (BMI). Expected variations in height between time-points were found within the margin of error for clinical measurement (mean difference of <3% for the cohort) and were accounted for by using the greater value to conservatively determine BMI. The BMI score was then converted to a percentile through population norms for age and gender published by the Centers for Disease Control and Prevention (CDC). 17 Each child's percentile was then classified into a weight category as per the CDC thresholds for overweight (85-94% inclusive), and obese (≥95 th %). Children at less than 85 th % were classified on this study as "lean."
Analysis of Minimal Residual Disease (MRD)
MRD was obtained during the study period from end of induction bone marrow specimens and was determined using 4-color multidimensional flow cytometry. Bone marrow specimens were analyzed with a dual-laser FACSCalibur flow cytometer with 
Results
Of 237 patients diagnosed with ALL during the study period, the final cohort consisted of 198 patients with BP-ALL following exclusion of ineligible (n=26) or not evaluable (n=13) patients (Supplemental Figure 1) . Demographic, disease, and treatment information for the cohort are presented in Table 1 . Approximately one-third of the cohort was either overweight (n=30, 15.2%) or obese (n=41, 20.7%) at time of diagnosis. Over half the cohort (n=110, 55.5%) gained weight during induction. Of those who were lean at time of diagnosis, 45 (22.7%) gained sufficient weight to be classified overweight (n=23, 18.1%) or obese (n=22, 17.3%) by end of induction (Supplemental Table 1 ). Of note, the study included a predominantly Hispanic population based on institutional demographics (n=157/198, 79.3%). As previously reported nationally 27 and in a recent ALL population, 28 obesity was more prevalent in our cohort in the Hispanic population.
Similarly consistent with national averages, obesity was more prevalent in our cohort in males, 27 adolescents (particularly those ≥ 13 years), 27 and in children with Down Syndrome. 29 No significant differences were found in NCI/Rome risk category and cytogenetic classification. Figure 1 ). Previously established predictors of early response to treatment such as starting WBC and cytogenetics were independently associated with MRD positivity in both multivariate models ( Table 2) .
Risk for Persistent MRD by Weight Status at Diagnosis
Risk for Persistent MRD by Weight Change during Induction
Weight change during induction was not found to be a significant predictor of MRD when controlling for starting weight (any weight loss compared to no change/weight gain, MV#1, OR 
Obesity and Event Free Survival
The BP-ALL cohort who were alive and event-free had a median follow-up of 1. Figure 2B ). Children who were lean and MRD negative had the best EFS, and MRD positivity and being overweight or obese were associated with poorer EFS.
Children who were overweight or obese and also MRD positive had the lowest EFS. As expected, NCI/Rome high risk and positive end-induction MRD were also both Table 3 ). Similar to the preceding analysis for MRD, there was no evidence that weight change during induction affected EFS after controlling for weight category at diagnosis.
Discussion
To our knowledge, this is the first report describing the association between obesity (via BMI) and the key prognostic marker of end of induction MRD in pediatric ALL. Children demonstrated either no effect of BMI on pharmacokinetics 30 or increased exposure to chemotherapy in the obese. [31] [32] [33] The latter may contribute to post-induction treatment failure as obese children have an increased risk for treatment-associated hepatic and pancreatic organ damage, two important dose-limiting toxicities; 3 this would not explain, however, our finding of decreased efficacy of induction chemotherapy in the obese.
Recent studies have therefore moved the focus from obese physiology to the "active" nature of adipose tissue itself, exploring adipokines and adipocyte-leukemia interactions. Adipocytes represent a major component of the bone marrow microenvironment, becoming particularly prominent following induction chemotherapy.
11
Leukemia cells have been shown to migrate toward and integrate within adipose tissue 10 increasing their immediate exposure to adipokines. Further, the presence of adipocytes markedly reduced the efficacy of chemotherapy agents that form the backbone of induction therapy (vincristine, dexamethasone, asparaginase, and daunorubicin) in in vitro co-culture and in vivo mouse models. [10] [11] [12] In addition, adipocytes and increased fat mass have been implicated in leukemogenic pathways 34 through the production of cytokines such as leptin, adiponectin, and interleukins. 35, 36 As bone marrow adiposity has been shown to correlate with total body fat in some, 37 but not all studies, 38 investigation is ongoing to determine whether leukemia evasion from therapy is due to the local adipose micro-environment or a global effect of obesity, for example, via circulating adipokines or altered immune function. Adipocyte-leukemia interactions represent a largely unexplored microenvironment that may mediate the adverse impact of obesity noted in pediatric ALL. In this context, our findings regarding the influence of obesity on early disease response has significant implications for any potential intervention. The adverse impact of obesity beginning at time of diagnosis on EFS and disease-related mortality has been demonstrated across multiple studies in pediatric ALL, [2] [3] [4] [5] 28 adult ALL, 39 and other hematological malignancies. [40] [41] [42] The newly identified effect of obesity to increase risk for persistent MRD raises the question of whether obese patients should be considered as a higher risk group from time of diagnosis, analogous to adolescents, who could potentially benefit from more intensive therapy during induction. Alternatively, and in contrast to immutable host and leukemia risk factors, the added risk from obesity may be modifiable and amenable to intervention as suggested from CCG1961 where normalization of BMI mitigated the adverse impact on EFS. 3 Over the past decade, treatment regimens for pediatric ALL have adopted a risk-stratified approach inclusive of MRD to provide effective treatment for those at highest risk for relapse and spare toxicity in others. 8, 22, [43] [44] [45] Approximately one in five children with SR-ALL remain MRD positive following induction therapy 22 and are routinely "escalated" to receive augmented and toxic intensive chemotherapy to reduce risk of relapse. 16, 45 Successful reduction of post-induction MRD through targeting the obese state may not only improve EFS but also spare a significant number of children with SR-ALL the need for augmented therapy associated with serious acute and late effects. 46, 47 Of note, our cohort consisted of a majority of Hispanic children -a population especially prone to obesity. 49 Emerging data on leukemia biology is lending increased support to this hypothesis through identification of an increased prevalence of new, higher-risk mutations in Hispanic children with ALL.
51-54 When we included ethnicity in the analysis, we found a negligible effect on the study's primary outcome of end-induction MRD. While this supports the independent association of obesity and persistent MRD, it also highlights certain populations wherein obesity is prevalent (such as Hispanic and adolescents and young adults) and who thus constitute particular at-risk groups.
This study reports a novel association between obesity at time of diagnosis and persistence of end-induction MRD, an important predictor of leukemia relapse.
Analyses of the influence of BMI on EFS or relapse risk in ALL are complicated by the continuous changes to BMI over the years of ALL therapy. The strength of this analysis therefore lies in the use of the proximal endpoint of MRD. While we could not exclude all heterogeneity (specifically in the use of either dexamethasone or prednisone in the most recent HR-ALL protocols), the relative uniformity of three or four drug induction therapy within NCI/Rome risk categories and the brief time period for the primary endpoint minimized the risk for confounding treatment-related variables that occur over prolonged therapy. These findings improve our understanding of the connection between obesity and ALL outcomes and should be confirmed in larger studies across different populations. For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From
